What Your Pharmacy Actually Pays for 20 Common Generics
Published November 21, 2026 路 9 min read 路 Figures last verified November 21, 2026
Reviewed by D.P., PharmD.
- The federal government publishes a national average acquisition-cost benchmark for drugs. It is called NADAC, and it is free to read.
- For 20 common generics, the NADAC estimate for the quantity shown runs from $0.30 to $3.01. Fifteen of the twenty are below $1.30.
- The pharmacy's cost is not your price. Dispensing fees, plan rules, and your copay or deductible are separate layers on top of it.
- The brand-name gap can be large. In this snapshot, brand Abilify has about 150 times the generic NADAC, and brand Crestor about 260 times.
- Use these numbers to compare payment routes, not to judge your pharmacy. A low acquisition cost does not mean a low price at your counter.
For 30 tablets of atorvastatin 10 mg, the November 18, 2026 NADAC works out to 68 cents. That is a national average acquisition-cost estimate, not a receipt from your pharmacy. Your counter price comes from a different set of prices and plan rules.
What a pharmacy pays to stock a drug and what you pay at the counter are different numbers. Your price depends on your coverage and the pharmacy's pricing. About one in four adults said they or someone in their household had problems paying for prescription drugs in the past 12 months, in a KFF poll conducted October 27 to November 2, 2025. This guide looks at a public acquisition-cost benchmark and where it stops being useful. For questions about a prescription, talk to your prescriber or pharmacist.
What NADAC is
NADAC stands for National Average Drug Acquisition Cost. CMS publishes weekly reference files based on a monthly nationwide survey of retail community pharmacy invoice prices. The files include weekly price updates between monthly survey releases. CMS currently uses a three-month moving average for generic monthly rate updates to reduce volatility. State Medicaid programs can use NADAC as a reference for pharmacy reimbursement. The data is free to download.
The week used for this guide is the file dated November 18, 2026. It covers 30,211 drug products, each identified by its National Drug Code, with a price per unit, meaning per tablet, capsule, or milliliter, and an effective date. Prices move week to week, so every figure here is a snapshot of that one week, not a permanent price.
Three limits matter. First, NADAC is an average. An individual pharmacy may have paid more or less than the published figure for the same drug. Second, it reflects invoice prices, so it does not capture every discount or rebate in the supply chain. Third, it is a cost benchmark, not a retail price. Nothing in the file says what a patient should pay.
The 20 generics
The table shows the NADAC per unit for 20 common generic drugs in the November 18, 2026 snapshot, multiplied by an example quantity. Quantities are for price math only, not dosing or supply-duration guidance. Your prescription may specify a different quantity. The per-unit figure is useful for comparing the same drug, strength and form across quantities.
On a narrow screen, swipe the table sideways to see all four columns.
| Drug and strength | NADAC per unit | Quantity shown | NADAC 脳 quantity |
|---|---|---|---|
| Atorvastatin 10 mg tablet | $0.02283 | 30 tablets | $0.68 |
| Amlodipine besylate 5 mg tablet | $0.01012 | 30 tablets | $0.30 |
| Lisinopril 10 mg tablet | $0.01806 | 30 tablets | $0.54 |
| Metformin HCl 500 mg tablet | $0.01482 | 60 tablets | $0.89 |
| Levothyroxine 50 mcg tablet | $0.04245 | 30 tablets | $1.27 |
| Omeprazole DR 20 mg capsule | $0.03116 | 30 capsules | $0.93 |
| Losartan potassium 50 mg tablet | $0.03357 | 30 tablets | $1.01 |
| Simvastatin 20 mg tablet | $0.03093 | 30 tablets | $0.93 |
| Gabapentin 300 mg capsule | $0.03342 | 90 capsules | $3.01 |
| Sertraline HCl 50 mg tablet | $0.03551 | 30 tablets | $1.07 |
| Amoxicillin 500 mg capsule | $0.07753 | 30 capsules | $2.33 |
| Azithromycin 250 mg tablet | $0.27108 | 6 tablets | $1.63 |
| Metoprolol succinate ER 25 mg tablet | $0.05409 | 30 tablets | $1.62 |
| Furosemide 40 mg tablet | $0.02932 | 30 tablets | $0.88 |
| Pantoprazole sodium DR 40 mg tablet | $0.03760 | 30 tablets | $1.13 |
| Escitalopram 10 mg tablet | $0.03869 | 30 tablets | $1.16 |
| Bupropion HCl XL 150 mg tablet | $0.07473 | 30 tablets | $2.24 |
| Trazodone 50 mg tablet | $0.02859 | 30 tablets | $0.86 |
| Hydrochlorothiazide 25 mg tablet | $0.01120 | 30 tablets | $0.34 |
| Montelukast sodium 10 mg tablet | $0.04307 | 30 tablets | $1.29 |
Fifteen of the twenty NADAC estimates are below $1.30 for the quantity shown. The lowest is amlodipine 5 mg at $0.30 for 30 tablets; the highest is gabapentin 300 mg at $3.01 for 90 capsules. These are national benchmark estimates, not each pharmacy's actual costs. A low acquisition-cost estimate does not guarantee a low copay, because copays are set under plan rules.
Why the pharmacy's cost is not your price
The tablets are only part of the cost of filling a prescription. A pharmacy also pays for staff, the building, and systems to check prescriptions and bill plans. Reimbursement can include a dispensing fee, with details that vary by program and contract. These operating costs and fees are not included in the NADAC per-unit figure.
Your price at the counter is set further downstream. If you use insurance, your plan's negotiated rate and your cost sharing decide what you owe. A copay is a flat amount set by the plan, and it does not track the drug's acquisition cost. Until a deductible is met, you may pay the plan's full negotiated price, which can be far above what the pharmacy paid. That gap is why a drug that cost the pharmacy under a dollar can still show a $15 copay. Our guide on why copays go up walks through the plan mechanics behind that.
Cash prices work differently again. A discount coupon or a cash-pay pharmacy sets its own price, and that price may be close to the acquisition cost or far above it. Comparing the cash price with the insured price for the same drug, strength, form, and quantity is the only comparison that means anything. Our GoodRx versus insurance guide and our Cost Plus Drugs versus GoodRx guide both use that same-drug, same-quantity rule.
A pharmacy benefit manager, or PBM, may manage a plan's pharmacy network and reimbursement. The difference between a pharmacy's reimbursement and its acquisition and dispensing costs is the pharmacy's margin. PBM spread pricing is different: it is the amount a PBM keeps when it bills a health plan more than it pays the pharmacy. NADAC alone cannot tell you either amount. Our guide on what a PBM is explains that role.
The brand-name gap
Competition among generic manufacturers can lower acquisition costs. The NADAC snapshot shows large gaps for these two brand-and-generic pairs at the same strength and form.
In the November 18, 2026 snapshot, Abilify 10 mg has a NADAC of $18.61552 per tablet, or $558.47 for 30 tablets. Generic aripiprazole 10 mg is $0.12366 per tablet, or $3.71 for 30. The brand benchmark is about 150 times the generic benchmark. Crestor 10 mg is $8.80478 per tablet, or $264.14 for 30; generic rosuvastatin 10 mg is $0.03377 per tablet, or $1.01 for 30. That ratio is about 260 to one. Quantity totals use the full per-unit figures, then round to cents.
Eliquis 5 mg has a NADAC of $5.52099 per tablet in this snapshot, or $331.26 for 60 tablets. No generic apixaban rate appears in that file. Absence from NADAC does not establish whether a generic has FDA approval or is available. Ask a pharmacist about current availability, and check your plan's formulary and cost sharing. Medicare Part D has separate spending rules, including the out-of-pocket cap explained in our Part D cap guide.
The lesson is not that every brand prescription should become a generic. Whether a generic version exists, whether it is on your plan's formulary, and whether your prescriber wrote the prescription for the brand or the generic are all separate questions, and only the prescriber and pharmacist can answer the clinical ones. The NADAC numbers show the size of the price difference when a generic does exist, which is why the formulary check matters before enrollment closes. Our guide on checking the drug formulary before you pick a plan covers that timing.
What to do with these numbers
First, use them as a reality check, not a price list. If a cash price for a common generic is far above the NADAC figure, compare one more option. Prices vary by pharmacy, and the acquisition cost is only one ingredient in the price you are quoted.
Second, compare insurance and cash prices for the same drug, strength, form and quantity. A cash purchase outside insurance is not automatically credited toward plan spending. Ask your plan whether it accepts receipts for possible reimbursement or spending credit, and confirm deductible and out-of-pocket-limit credit separately. Save receipts. A pharmacy may also be able to provide an annual spending summary for your records.
Third, recheck prices when you refill and coverage when your plan renews or changes. NADAC files are published weekly, but a particular drug's benchmark may stay unchanged across releases. The figures here were checked November 21, 2026 using only the November 18 snapshot. They are not permanent prices, and they do not predict the direction of future changes.
This guide explains prescription pricing and payment systems. It does not recommend a drug, treatment, pharmacy, or insurance decision. Ask your prescriber or pharmacist about the prescription and your plan about coverage and spending credit. Full disclaimer.
Sources
Sources checked November 21, 2026. Prices and policies may change.
- CMS Medicaid, NADAC (National Average Drug Acquisition Cost) 2026 (weekly reference file dated November 18, 2026; 30,211 drug products; all per-unit figures and brand-to-generic comparisons in this guide)
- CMS Medicaid, Retail Price Survey (nationwide survey of retail community pharmacy prices; weekly NADAC updates)
- CMS Medicaid, Pharmacy Pricing (NADAC program description; monthly and weekly posting schedule)
- KFF, Health Tracking Poll: Health Care Costs in the Current Moment of Economic Anxiety (26 percent of adults reported problems affording prescription drugs in the past 12 months; October 27 to November 2, 2025 poll)
- CMS, spread-pricing guidance (Distinguishes health-plan payments to PBMs from PBM pharmacy reimbursement.)
- GoodRx Support, deductible credit (Cash purchases are not automatically credited; plans may accept receipt submissions.)